Contracts between manufacturers and payers, where the price of a drug is linked to its efficacy, are becoming increasingly important to ensure access to medicines and reduce healthcare costs. In this case, the manufacturer is paid in full only if the drug works for the patients. Now the question arises as to whether value-based contracts lead to general cost fairness or end up in a price trap. In addition, we also address current topics. We are looking forward to an exciting day with interesting presentations and enough time for discussions with speakers and participants.
